Literature DB >> 26996894

[Asymmetric dimethylarginine: predictor of cardiovascular diseases?].

Balázs Németh1, Péter Kustán2, Ádám Németh3, Zsófia Lenkey3, Attila Cziráki3, István Kiss1, Endre Sulyok4, Zénó Ajtay3,5.   

Abstract

Cardiovascular diseases are the most common diseases worldwide. They are responsible for one third of global deaths and they are the leading cause of disability, too. The usage of different levels of prevention in combination with effective risk assessment improved these statistical data. Risk assessment based on classic risk factors has recently been supported with several new markers, such as asymmetric dimethylarginine, which is an endogenous competitive inhibitor of nitric oxide synthase. Elevated levels of asymmetric dimethylarginine have been reported in obese, smoker, hypercholesterolemic, hypertensive and diabetic patients. According to previous studies, asymmetric dimethylarginine is a suitable indicator of endothelial dysfunction, which is held to be the preceding condition before atherosclerosis. Several researches found positive correlation between higher levels of asymmetric dimethylarginine and coronary artery disease onset, or progression of existing coronary disease. According to a study involving 3000 patients, asymmetric dimethylarginine is an independent risk factor of cardiovascular mortality in patients with coronary artery disease. This article summarizes the role of asymmetric dimethylarginine in prediction of cardiovascular diseases, and underlines its importance in cardiovascular prevention.

Entities:  

Keywords:  asymmetric dimethylarginine; aszimmetrikus dimetilarginin; kockázatbecslés; oxidative stress; oxidatív stressz; risk stratification

Mesh:

Substances:

Year:  2016        PMID: 26996894     DOI: 10.1556/650.2016.30396

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  2 in total

1.  Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment.

Authors:  Balazs Nemeth; Istvan Kiss; Timea Jencsik; Ivan Peter; Zita Kreska; Tamas Koszegi; Attila Miseta; Peter Kustan; Imre Boncz; Andrea Laczo; Zeno Ajtay
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

2.  Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?

Authors:  Balázs Németh; Iván Péter; Imre Boncz; Anna Jagicza; István Kiss; Ágnes Csergő; Tamás Kőszegi; Péter Kustán; Iván G Horváth; Zénó Ajtay
Journal:  Ther Clin Risk Manag       Date:  2019-07-05       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.